Sequential Combination Therapy With PD-1 Antibody and Peg-IFNα in CHB Patients
Status:
RECRUITING
Trial end date:
2025-12-15
Target enrollment:
Participant gender:
Summary
This is a prospective study to evaluate the safety and efficacy of Sintilimab (PD-1 antibody) in sequential combination with Peg-IFNα-2b in NA-supressed CHB patients who had previously received Peg-IFNα therapy.